Figure 2 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Year: 2026
Type: other
Abstract: Clinical outcomes of berzosertib + carboplatin and docetaxel + carboplatin. A and B, Waterfall plots of (A) maximal PSA decline and (B) decline in measurable lesions by RECIST 1.1 from baseline. One patient in arm B (Y, far right) had an unconfirmed PR at cycle 8, followed by progressive disease. C–E, Kaplan–Meier estimates of (C) rPFS, (D) PFS by PCWG3 criteria (“no longer clinically benefiting,” i.e., radiographic or clinical/symptomatic progression), and (E) OS.
Authors: Atish D. Choudhury, Caiwei Zhong, Wanling Xie, Bose S. Kochupurakkal, Peter I-Fan Wu, Irbaz Bin Riaz, Ruolin Liu, David D. Yang, Edmund Folefac, Daniel Lee, Mamta Parikh, David J. Einstein, Elizabeth R. Kessler, Tina Mayer, Rana R. McKay, Amanda Pace, Kent W. Mouw, Li Chen, Viktor A. Adalsteinsson, Eliezer M. Van Allen, Charles A. Kunos, Steven D. Gore, Biswajit Das, Alan D’Andrea, Mary-Ellen Taplin, Geoffrey I. Shapiro
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7213563364
Cites:
Cited by:
Related to: